Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 11/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.34 |
| ▸ | MIF | P14174 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660287 | 0.88 | NOD2 (0.38) | NOD2NOD1UCHL1MIFGPR119 | |
| SCHEMBL3755529 | 0.83 | NR1H2 (0.37) | NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL3660868 | 0.83 | NOD2 (0.34) | NOD2NOD1UCHL1MIF | |
| SCHEMBL12312106 | 0.83 | NOD2 (0.34) | NOD2NOD1NR1H2NR1H3UCHL1 | |
| SCHEMBL3657600 | 0.81 | DRD2 (0.37) | NOD2NOD1GPR119 | |
| SCHEMBL3661897 | 0.81 | NR1H2 (0.40) | NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL3752329 | 0.79 | S1PR1 (0.53) | — | |
| SCHEMBL3660988 | 0.79 | NR1H2 (0.36) | NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL3660992 | 0.79 | NR1H2 (0.36) | NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL2917440 | 0.72 | MEN1 (0.38) | NR1H2NR1H3UCHL1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009080728-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | NOD2 817/4885NOD1 520/4885NR1H2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.